Member Info for liquid1

Sep 27, 2019
Plans for Plastics to Hydrogen Facility at Protos Submitted
Peel Environmental – part of Peel L&P – working in partnership with Waste2Tricity has submitted plans for a waste plastic to hydrogen facility at its 54-hectare Protos site near Ellesmere Port which would help reduce fossil fuel consumption and create jobs.

==================================

Market will like the news as it's a concrete GO!

sp will rise!!

Let's await the RNS 7:00 tomorrow!

Anyone care to guess the approval target?

2p?
3p?
Or more

Awesome

Next generation technology! Who the F is going to say no to this!

Roll on RNS

NT to buy!

sp wants to rise

Hope we get a positive RNS tomorrow to get the Mcap moving up and away

APPROVAL NEARS FOR LATEST PROTOS FACILITY
27 Feb 2020 North West Property Matthew Ord
Approval nears for latest Protos facility
Approval has been recommended for the development of a hydrogen production facility and electricity generating plant at Protos.

Peel Environmental and Waste2Tricity are behind the application, which is earmarked for a plot identified in the wider masterplan for the development of business and office space.

However, Peel Environmental has since collaborated with the University of Chester and based its main Protos base at Thornton Science Park, leaving the plot available for other development.

The proposed development – which would be operated by Waste2Tricity – would employ an advanced thermal treatment process to generate hydrogen and electricity from waste plastic not suitable for recycling.

The fuel feedstock would comprise residual waste plastic from a range of locally derived sources. If approved, the facility would enable up to two tonnes of hydrogen to be exported every day; a sufficient amount to fuel circa 18,000 HGV miles.

While not part of the application, if the demand for hydrogen develops then it "may be possible for a vehicle hydrogen vehicle filling station to be developed within Protos or for hydrogen to be fed via pipe to a direct user or into the local gas distribution network", according to a planning statement drawn up by Axis on behalf of the developers.

"The North West is already poised to bring forward two hydrogen energy projects," added the document. "The proposed development would contribute further towards establishing the North West, and more specifically Cheshire West and Chester, as the leader in this emerging industry."

The facility would have the potential to provide direct employment for 14 staff, while the entire fabrication and construction period would support more than 100 temporary positions.

The application is set to go before Cheshire West and Chester Council's planning committee on 3 February.

A report to the authority said: "The facility would utilise waste plastics, which are not suitable for recycling, in an advanced thermal treatment process. As such, the proposal would positively contribute to meeting climate change initiatives and waste recovery in terms of managing waste and energy production.

"It would develop a safeguarded site and support economic growth."

Approval has been recommended

https://www.insidermedia.com/news/north-west/approval-nears-for-latest-protos-facility

Mcap far too low compared to peers!

Tomorrow with a thumbs up, this should be much higher

****************************/articles/alan-green-talks-about-eddie-stobart-logistics-byotrol-astrazeneca-and-metro-bank-2cdfd86/

I can’t believe the stupidity on UK government not authorising PrimerDesign which is accurate for the virus regardless of the presence of symptoms, and within 2 hours!!!

Dr. Schaffner said he had a patient come in earlier this week who had developed symptoms of an upper respiratory infection after traveling to Italy, where a cluster of coronavirus infections has been observed. He referred the patient to the state laboratory, but officials there said she could not be tested because she did not meet the C.D.C. testing criteria at the time.

The testing limitations may have also prevented health officials from detecting cases earlier on in California, Oregon and Washington state, where people were found to have coronavirus infections despite having no history of travel to China or exposure to anyone with a confirmed infection. Those patients did not meet C.D.C.’s earlier criteria for testing. One person in Washington has since died of the coronavirus.

“If we had the ability to test earlier, I’m sure we would have identified patients earlier,” said Dr. Jeff Duchin, the health officer for public health in Seattle and King County, where the first death was reported on Saturday.

Both C.D.C. and the F.D.A. did have the option of adopting the test approved by the World Health Organization, and public health experts said it was unclear why the agencies decided not to do so. Instead, the C.D.C. chose to forge ahead with its own test, and promised to distribute replacement kits soon.

“In retrospect, it seems like a bad decision,” said one high-ranking C.D.C. official who requested anonymity and was not authorized to talk to the media.

https://www.nytimes.com/2020/02/29/health/fda-coronavirus-testing.html

https://www.google.co.uk/amp/s/www.nbcnews.com/news/amp/ncna1145931

First coronavirus death in the U.S. happens in Washington state
The announcement came from health officials in Washington state health officials.

Novacyt Products Pass Regulatory Muster in US, China
Feb 23, 2017 | staff reporter
NEW YORK (360Dx) – Novacyt today announced regulatory actions by US and Chinese regulators for two of its products.

In the US, the firm has registered its Novaprep HQ+ Orange vial as a class I device with the US Food and Drug Administration. Providers who can qualify the vial for cytology or molecular use in the US can now purchase the product. Novacyt plans to seek a commercialization partner for the Novaprep vial and media system, the company said.

Novacyt also said that the Novaprep system has been approved by the Chinese Food and Drug Administration for non-gynecological cancer testing in China. The technology was previously approved in 2015 by CFDA for cervical cancer screening. The new approval means Novacyt can market the Novaprep system other cancers through its China subsidiary.

"These regulatory approvals expand the marketing and distribution opportunities for the Novaprep platform in cervical cancer screening, which is the largest, and in certain markets, one of the fastest growing cancer screening markets," Novacyt Group CEO Graham Mullis said in a statement. "The additional non-gynecological approval in China for Novaprep brings the technology to multiple new cancer markets and reinforces our direct sales investment in China, which is already giving substantial growth of 100 percent in 2016 and is expected to deliver more in 2017."

https://www.360dx.com/regulatory-news/novacyt-products-pass-regulatory-muster-us-china#.Xlpoh2j7SUk

Feb. 28, 2020

PARIS — Biotechnology company Novacyt on Friday announced deals for its "Primerdesign" product which is aimed at testing for the coronavirus currently afflicting China and other parts of the world.

Novacyt said it had signed its first major distribution agreement for the COVID-19 coronavirus test with a global life sciences company to supply the test to two Asian territories outside mainland China, sending its shares to record highs.

It added that initial sales from this, which are subject to local emergency use approval, were anticipated to total 2.1 million pounds ($2.73 million) in the first six months of the agreement.

Novacyt also announced a manufacturing deal with an unnamed U.S. healthcare company.

"The two contracts announced today reinforce how quickly the response to this virus is developing and shows our commitment to support these efforts anywhere in the world," Novacyt CEO Graham Mullis said.

https://www.nytimes.com/reuters/2020/02/28/world/europe/28reuters-china-health-novacyt.html

Coronavirus: these small French stocks that are booming on the stock market
BOURSORAMA • 02/28/2020 at 15:45

Novacyt
While the number of cases of contamination continues to increase worldwide, the company Novacyt, specialist in clinical diagnosis, announces at the end of January the launch of a new molecular test for the detection of coronavirus 2019.

The coronavirus test, developed by its subsidiary Primerdesign, "has the capacity to detect only the 2019 strain of the virus", which, according to the company, "differentiates it from other current tests which are less specific and may also react to other related species giving rise to a false diagnosis'. In addition, the group reports that a result can be generated in less than two hours. On January 31, the stock jumped 81.12% ...

A few days later, Novacyt indicated that it had received orders for 33,000 tests and requests for quotes for an additional 32,000 tests from more than 30 countries with a high conversion rate from quotes to orders. The group also announced that the launch of the nCoV test with CE marking will take place on February 17. With this marking, the company's COVID-19 test can be used directly by laboratories and hospitals to test patients without the need for validation by clinicians. On February 17, the stock climbed 56.81%. It fell by 26% on the 19th, by 50.9% on the 20th before regaining 84% on the 21st: sensitive souls abstain ...

On February 28, Novacyt announced the signing of a major distribution agreement in Asia and an Original Equipment Manufacturer (OEM) agreement with an American healthcare group. In addition, the statement said, "the Primerdesign test is currently being reviewed by the US Food and Drug Administration (FDA) for emergency use approval." This will open the American market to the test for the clinical diagnosis of COVID-19.

https://www.boursorama.com/bourse/actualites/coronavirus-ces-petites-valeurs-francaises-qui-flambent-en-bourse-40c7b8a5fe5f1946f4a543af4a428852?symbol=1rPALNOV

NOVACYT
1.7460 EUR
+ 33.08%
FR0010397232 ALNOV
EURONEXT PARIS REAL-TIME DATA

Reckon LSE has the Coronavirus!

Everything is stuck on LSE

9.30am: Novacyt surges again as its coronavirus diagnostic test proves popular

Novacyt SA (LON:NCYT), up 14% at 131.42p, was a rare riser on another bloodbath for stock markets on Friday, after the firm clinched a major distribution deal for its coronavirus diagnostic test.

The company has signed a major distribution agreement in Asia for the novel coronavirus (COVID-19) test developed by Primerdesign, its molecular diagnostics division, and has also bagged an original equipment manufacturer agreement with a US healthcare group.

Initial sales from the Asian distribution deal, which are subject to local emergency use approval, are anticipated to be £2.1mln during the first six months of the agreement. It is expected that the first sales under this agreement will take place next month.

Results revealed that half year revenues for the six months to May 31, 2019, were £421.3m, compared with £334.5m in the previous period.

NOVACYT
1.3120 (c) EUR
0.00%
THEORETICAL OPENING 1.7600
FR0010397232 ALNOV
EURONEXT PARIS REAL-TIME DATA